This suggests that combining APC11 with agents such as TASIN-1 or Dvl–cholesterol inhibitors may provide a synergistic therapeutic strategy that simultaneously targets both oncogenic signaling and immune escape in APC-mutant CRC. This evidence concerns the gene APC and colorectal carcinoma.